News | August 06, 2024
Indraprastha Medical Corporation posts Q1 FY25 PAT at Rs. 44.77 Cr
Indraprastha Medical Corporation has reported total income of Rs. 352.98 crores during the quarter ended June 30, 2024
Indraprastha Medical Corporation has reported total income of Rs. 352.98 crores during the quarter ended June 30, 2024
Cupid Ltd has reported total income of Rs. 44.02 crores during the quarter ended June 30, 2024
SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024
Being the first approved applicant, Lupin is eligible for 180 days of CGT exclusivity
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept
Nelarabine is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia
Sun Pharmaceutical Industries has reported total income of Rs. 13,185.30 crores during the period ended June 30, 2024
Subscribe To Our Newsletter & Stay Updated
